Incidence of Viral and Fungal Infections following Busulfan-Based Reduced-Intensity versus Myeloablative Conditioning in Pediatric Allogeneic Stem Cell Transplantation Recipients

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 12, 2009, Pages 1587-1595

  Satwani, Prakash ^a   Baldinger, Leah ^a   Freedman, Jason ^a   Jacobson, Judith S ^b   Guerra, Jon ^a   van de Ven, Carmella ^a   Morris, Erin ^a   Garvin, James ^a   George, Diane ^a   Bradley, M Brigid ^a   Bhatia, Monica ^a   Tallamy, Bradford ^a   Schwartz, Joseph ^a   Jin, Zhezhen ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

Allogeneic stem cell transplantation; Infection; Myeloablative; Reduced intensity

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELLULAR IMMUNITY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; PROBABILITY; RECIPIENT; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SCHOOL CHILD; VIRUS INFECTION;

BUSULFAN; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MULTIVARIATE ANALYSIS; MYCOSES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; VIRUS DISEASES;

EID: 70350572382     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.08.006     Document Type: Article

References (40)

1. Champlin R., Khouri I., Shimoni A., et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111 (2000) 18-29
2. Satwani P., Harrison L., Morris E., et al. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 11 (2005) 403-422
3. Satwani P., Cooper N., Rao K., et al. Reduced-intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 41 (2008) 173-182
4. Satwani P., Morris E., Bradley M.B., et al. Reduced-intensity and nonmyeloablative allogeneic stem cell transplantation in children and adolescents with malignant and nonmalignant diseases. Pediatr Blood Cancer 50 (2008) 1-8
5. Bradley M.B., and Cairo M.S. Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant 41 (2008) 149-158
6. Del Toro G., Satwani P., Harrison L., et al. A pilot study of reduced-intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 33 (2004) 613-622
7. + acute myeloid leukemia. Clin Cancer Res 11 (2005) 7164s-7170s
8. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
9. Nagler A., Aker M., Or R., et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 29 (2001) 362-370
10. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99 (2002) 1978-1985
11. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1 (1999) 165-178
12. Einsele H., Ehninger G., Steidle M., et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 82 (1993) 1672-1678
13. Winston D.J., Young J.A., Pullarkat V., et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111 (2008) 5403-5410
14. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 23 (2004) 583-588
15. Hoffman J.A., Shah A.J., Ross L.A., et al. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7 (2001) 388-394
16. Wingard J.R. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 5 (1999) 55-68
17. Wald A., Leisenring W., van Burik J.A., et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175 (1997) 1459-1466
18. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8 (2002) 512-520
19. Osunkwo I., Bessmertny O., Harrison L., et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 10 (2004) 246-258
20. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18 (1974) 295-304
21. Waxman I., Militano O., Baldinger L., et al. Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. Pediatr Transplant 13 (2009) 464-474
22. Roman E., Osunkwo I., Militano O., et al. Liposomal amphotericin B prophylaxis of invasive mold infections in children post-allogeneic stem cell transplantation. Pediatr Blood Cancer 50 (2008) 325-330
23. Shereck E.B., Cooney E., van de Ven C., et al. A pilot phase II study of alternate-day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 49 (2007) 306-312
24. Boeckh M., and Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103 (2004) 2003-2008
25. Ljungman P., Ward K.N., Crooks B.N., et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 28 (2001) 479-484
26. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335 (1996) 157-166
27. Locatelli F., Rocha V., Chastang C., et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 93 (1999) 3662-3671
28. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
29. Satwani P., Tallamy B., Kohl V., et al. Reduced-intensity conditioning (RIC) allogeneic stem cell transplantation in pediatric recipients is associated with very low early mortality and high donor chimerism. [abstract]. Pediatr Blood Cancer (2008). Published online (0.149) at www143.interscience.wiley.com/journal/117935000/grouphome/home.html Accessed
30. Kennedy-Nasser A.A., Bollard C.M., Myers G.D., et al. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant 14 (2008) 1245-1252
31. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102 (2003) 827-833
32. Martino R., Caballero M.D., Canals C., et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 28 (2001) 341-347
33. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101 (2003) 1620-1629
34. Schetelig J., Oswald O., Steuer N., et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 32 (2003) 695-701
35. Busca A., Locatelli F., Barbui A., et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 5 (2003) 132-139
36. Frere P., Baron F., Bonnet C., et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant 37 (2006) 411-418
37. Petersen S.L., Madsen H.O., Ryder L.P., et al. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution. Br J Haematol 125 (2004) 225-231
38. Cohen J., Gandhi M., Naik P., et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 129 (2005) 229-239
39. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99 (2002) 4357-4363
40. Shenoy S., Grossman W.J., DiPersio J., et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 35 (2005) 345-352